Non-Pharmacological Therapy for Atrial Fibrillation: Managing the Left Atrial Appendage

Table 2

Summary of antiplatelet/anticoagulation requirements and endocarditis prophylaxis for each percutaneous device.

	Aspirin	Clopidogrel	Warfarin	Endocarditis Prophylaxis
AMPLATZER septal occluder [28]	Few months indefinitely depending on treating centre	None, few months depending on treating centre	None, 6 weeks depending on treating centre	Few months
PLAATO [30]	300–325 mg daily indefinitely	75 mg for 6 months at North American centres and at operator’s discretion at European centres	Nil	6 months at North American centres and at operator’s discretion at European centres
WATCHMAN [33]	81–325 mg daily indefinitely	75 mg for 6 months	At least 45 days. Discontinued at 45 days if follow up TEE shows <5 mm of peridevice flow	Nil
AMPLATZER cardiac plug [35]	Not specified	Not specified	Not specified	Not specified
Coherex Wave Crest	75–325 mg daily indefinitely	75 mg daily for 90 days if not on warfarin	If previously on warfarin with a history of stroke or TIA, continue warfarin until LAA closure demonstrated on TEE	Nil
LARIAT	Indefinitely	Nil	If previous embolic events whilst on OAC and no contraindication or intolerance, OAC continued regardless of procedural success	Nil

TIA: transient ischaemic attack and OAC: oral anticoagulant.